Z S Mo, D Y Xie, B L Lin, X G Dou, M B Wan, J J Jiang, Y R Zhao, H Tang, H Zhuang, Z L Gao
{"title":"[中国慢性乙型肝炎的治疗策略、实践及临床治愈前景]。","authors":"Z S Mo, D Y Xie, B L Lin, X G Dou, M B Wan, J J Jiang, Y R Zhao, H Tang, H Zhuang, Z L Gao","doi":"10.3760/cma.j.cn501113-20240325-00156","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical cure (herein referred to as functional cure) is currently recognized as the ideal therapeutic goal by the guidelines for the prevention and treatment of chronic hepatitis B (CHB) at home and abroad. China has achieved significant results in research and exploration based on pegylated interferon alpha therapeutic strategies to promote the effectiveness of CHB clinical cure rates in clinical practice. The summary and optimization of clinical cure strategies in different clinical type classifications, as well as the exploration of clinical cure continuity and long-term outcomes, are of great significance for solving the current bottleneck problem and our future efforts in the developmental directions of clinical cure in CHB populations.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 5","pages":"411-417"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Therapeutic strategies, practice, and prospect of a clinical cure for chronic hepatitis B in China].\",\"authors\":\"Z S Mo, D Y Xie, B L Lin, X G Dou, M B Wan, J J Jiang, Y R Zhao, H Tang, H Zhuang, Z L Gao\",\"doi\":\"10.3760/cma.j.cn501113-20240325-00156\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clinical cure (herein referred to as functional cure) is currently recognized as the ideal therapeutic goal by the guidelines for the prevention and treatment of chronic hepatitis B (CHB) at home and abroad. China has achieved significant results in research and exploration based on pegylated interferon alpha therapeutic strategies to promote the effectiveness of CHB clinical cure rates in clinical practice. The summary and optimization of clinical cure strategies in different clinical type classifications, as well as the exploration of clinical cure continuity and long-term outcomes, are of great significance for solving the current bottleneck problem and our future efforts in the developmental directions of clinical cure in CHB populations.</p>\",\"PeriodicalId\":24006,\"journal\":{\"name\":\"中华肝脏病杂志\",\"volume\":\"32 5\",\"pages\":\"411-417\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华肝脏病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn501113-20240325-00156\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20240325-00156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
[Therapeutic strategies, practice, and prospect of a clinical cure for chronic hepatitis B in China].
Clinical cure (herein referred to as functional cure) is currently recognized as the ideal therapeutic goal by the guidelines for the prevention and treatment of chronic hepatitis B (CHB) at home and abroad. China has achieved significant results in research and exploration based on pegylated interferon alpha therapeutic strategies to promote the effectiveness of CHB clinical cure rates in clinical practice. The summary and optimization of clinical cure strategies in different clinical type classifications, as well as the exploration of clinical cure continuity and long-term outcomes, are of great significance for solving the current bottleneck problem and our future efforts in the developmental directions of clinical cure in CHB populations.